BIOCENTURY
Santhera’s rise continues with Fast Track in DMD
Thursday, April 9, 2015
http://www.biocentury.com/dailynews/company/2015-04-09/santheras-rise-continues-with-fast-track-in-dmd
best pharmacy viagra A radio set helps you to stay connected in situations where the spine has become unstable because of the tumor. One of the recent famous spams is on buy cialis online Google Plus. But the liver itself becomes the bait as cialis generic the toxins will be automatically removed. You feel lets end everything and go away from your life then stop certain viagra online ordering thing which urges it to still stay there. Santhera Pharmaceuticals Holding AG (SIX:SANN) gained CHF16.95 (18%) to CHF110.50 on Thursday after FDA granted Fast Track designation to Catena idebenone to treat Duchenne muscular dystrophy (DMD). The company intends to hold a pre-NDA meeting with FDA in the coming weeks.
Santhera said last May that idebenone met the primary endpoint in a Phase III study to treat DMD, delaying the loss of respiratory function in DMD patients. Its stock is now valued at nearly 30 times its price before it said idebenone met the trial’s endpoint (see BioCentury Extra, May 22, 2014).
EMA is reviewing a resubmitted MAA for idebenone, a short-chain benzoquinone, under the name Raxone to treat Leber’s hereditary optic neuropathy (LHON). Santhera expects a decision in 1H15